Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1996 1
1997 1
1998 4
2006 1
2007 1
2011 1
2013 2
2016 2
2019 1
2020 1
2021 2
2022 2
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

22 results
Results by year
Filters applied: . Clear all
Page 1
Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants.
Mizoue T, Yamamoto S, Konishi M, Oshiro Y, Inamura N, Nemoto T, Ozeki M, Horii K, Okudera K, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. Mizoue T, et al. Among authors: aoyanagi n. J Infect. 2022 Nov;85(5):573-607. doi: 10.1016/j.jinf.2022.08.015. Epub 2022 Aug 20. J Infect. 2022. PMID: 35995310 Free PMC article. No abstract available.
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, Takeuchi JS, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: aoyanagi n. Clin Infect Dis. 2022 Aug 24;75(1):e683-e691. doi: 10.1093/cid/ciab1048. Clin Infect Dis. 2022. PMID: 34950947 Free PMC article.
Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.
Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, Yugawa K, Wang H, Oda Y, Yoshizumi T, Maehara Y, Kanto T. Mano Y, et al. Among authors: aoyanagi n. J Gastroenterol. 2019 Nov;54(11):1007-1018. doi: 10.1007/s00535-019-01579-5. Epub 2019 Apr 2. J Gastroenterol. 2019. PMID: 30941514
Venoplasty of recipient portal vein in living-related liver transplantation.
Harihara Y, Makuuchi M, Takayama T, Kawarasaki H, Kubota K, Ito M, Tanaka H, Aoyanagi N, Matsukura A, Kita Y, Saiura A, Sakamoto Y, Kobayashi T, Hashizume K. Harihara Y, et al. Among authors: aoyanagi n. Transplant Proc. 1998 Nov;30(7):3206. doi: 10.1016/s0041-1345(98)00996-8. Transplant Proc. 1998. PMID: 9838417 No abstract available.
Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.
Nomura M, Sumiya R, Ono H, Nagai T, Kumazawa K, Shimizu A, Endo D, Aoyanagi N. Nomura M, et al. Among authors: aoyanagi n. World J Surg Oncol. 2021 Jan 2;19(1):4. doi: 10.1186/s12957-020-02114-0. World J Surg Oncol. 2021. PMID: 33388058 Free PMC article.
A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial).
Mise Y, Hasegawa K, Saiura A, Oba M, Yamamoto J, Nomura Y, Takayama T, Hashiguchi Y, Shibasaki M, Sakamoto H, Yamagata S, Aoyanagi N, Kaneko H, Koyama H, Miyagawa S, Shinozaki E, Yoshida S, Nozawa H, Kokudo N. Mise Y, et al. Among authors: aoyanagi n. Ann Surg Oncol. 2020 Oct;27(11):4188-4195. doi: 10.1245/s10434-020-08627-y. Epub 2020 Jun 8. Ann Surg Oncol. 2020. PMID: 32514802 Clinical Trial.
22 results